X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GLENMARK PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GLENMARK PHARMA CADILA HEALTHCARE/
GLENMARK PHARMA
 
P/E (TTM) x 13.1 12.4 105.3% View Chart
P/BV x 2.7 2.2 123.3% View Chart
Dividend Yield % 1.5 0.5 316.3%  

Financials

 CADILA HEALTHCARE   GLENMARK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
GLENMARK PHARMA
Mar-18
CADILA HEALTHCARE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs558930 60.0%   
Low Rs362517 69.9%   
Sales per share (Unadj.) Rs116.3322.6 36.0%  
Earnings per share (Unadj.) Rs17.928.5 62.7%  
Cash flow per share (Unadj.) Rs23.139.2 59.0%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.80.3 275.5%  
Book value per share (Unadj.) Rs85.4183.0 46.7%  
Shares outstanding (eoy) m1,023.74282.17 362.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.02.2 176.2%   
Avg P/E ratio x25.725.4 101.3%  
P/CF ratio (eoy) x19.918.5 107.6%  
Price / Book Value ratio x5.44.0 136.1%  
Dividend payout %19.67.0 279.0%   
Avg Mkt Cap Rs m470,664204,206 230.5%   
No. of employees `00011.813.7 86.2%   
Total wages/salary Rs m18,54518,718 99.1%   
Avg. sales/employee Rs Th10,072.76,636.8 151.8%   
Avg. wages/employee Rs Th1,569.11,364.7 115.0%   
Avg. net profit/employee Rs Th1,547.7586.1 264.1%   
INCOME DATA
Net Sales Rs m119,04991,031 130.8%  
Other income Rs m1,132914 123.9%   
Total revenues Rs m120,18191,945 130.7%   
Gross profit Rs m28,47516,154 176.3%  
Depreciation Rs m5,3883,019 178.5%   
Interest Rs m9112,856 31.9%   
Profit before tax Rs m23,30811,193 208.2%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6443,155 178.9%   
Profit after tax Rs m18,2928,039 227.5%  
Gross profit margin %23.917.7 134.8%  
Effective tax rate %24.228.2 85.9%   
Net profit margin %15.48.8 174.0%  
BALANCE SHEET DATA
Current assets Rs m82,00569,887 117.3%   
Current liabilities Rs m60,72032,879 184.7%   
Net working cap to sales %17.940.7 44.0%  
Current ratio x1.42.1 63.5%  
Inventory Days Days7381 89.8%  
Debtors Days Days9893 105.1%  
Net fixed assets Rs m83,70328,892 289.7%   
Share capital Rs m1,024282 362.9%   
"Free" reserves Rs m86,42151,353 168.3%   
Net worth Rs m87,44551,635 169.4%   
Long term debt Rs m25,55141,418 61.7%   
Total assets Rs m180,653125,954 143.4%  
Interest coverage x26.64.9 540.4%   
Debt to equity ratio x0.30.8 36.4%  
Sales to assets ratio x0.70.7 91.2%   
Return on assets %10.68.6 122.9%  
Return on equity %20.915.6 134.4%  
Return on capital %22.015.1 145.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68336,317 117.5%   
Fx outflow Rs m11,2429,720 115.7%   
Net fx Rs m31,44126,598 118.2%   
CASH FLOW
From Operations Rs m9,19316,481 55.8%  
From Investments Rs m-9,737-10,133 96.1%  
From Financial Activity Rs m515-4,685 -11.0%  
Net Cashflow Rs m-291,770 -1.6%  

Share Holding

Indian Promoters % 74.8 48.3 154.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 6.9 120.3%  
FIIs % 5.9 34.4 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.5 104.8%  
Shareholders   44,069 56,727 77.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   BIOCON   WOCKHARDT  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips below 38,000-Mark; Yes Bank Jumps 9%(12:30 pm)

Share markets in India are presently trading deep in the red as investors were disappointed after the government refused any respite to foreign investors.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jul 22, 2019 01:57 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS